CA3160801A1 - Novel functionalized lactams as modulators of the 5-hydroxytryptamine receptor 7 and their method of use - Google Patents
Novel functionalized lactams as modulators of the 5-hydroxytryptamine receptor 7 and their method of useInfo
- Publication number
- CA3160801A1 CA3160801A1 CA3160801A CA3160801A CA3160801A1 CA 3160801 A1 CA3160801 A1 CA 3160801A1 CA 3160801 A CA3160801 A CA 3160801A CA 3160801 A CA3160801 A CA 3160801A CA 3160801 A1 CA3160801 A1 CA 3160801A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- group
- unsubstituted
- cycloalkyl
- atoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/267—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962934997P | 2019-11-13 | 2019-11-13 | |
| US62/934,997 | 2019-11-13 | ||
| PCT/US2020/060270 WO2021097116A1 (en) | 2019-11-13 | 2020-11-12 | Novel functionalized lactams as modulators of the 5-hydroxytryptamine receptor 7 and their method of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3160801A1 true CA3160801A1 (en) | 2021-05-20 |
Family
ID=74068668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3160801A Pending CA3160801A1 (en) | 2019-11-13 | 2020-11-12 | Novel functionalized lactams as modulators of the 5-hydroxytryptamine receptor 7 and their method of use |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230002383A1 (https=) |
| EP (1) | EP4058455A1 (https=) |
| JP (2) | JP7730811B2 (https=) |
| KR (1) | KR20220113702A (https=) |
| CN (1) | CN115003675A (https=) |
| AU (1) | AU2020381460A1 (https=) |
| BR (1) | BR112022009374A2 (https=) |
| CA (1) | CA3160801A1 (https=) |
| IL (1) | IL292811A (https=) |
| MX (1) | MX2022005820A (https=) |
| TW (1) | TWI905129B (https=) |
| WO (1) | WO2021097116A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA49019A (fr) | 2017-03-21 | 2020-02-05 | Univ Temple | Nouveaux modulateurs du récepteur sigma 2 et leur procédé d'utilisation |
| EA202092328A1 (ru) | 2018-05-11 | 2021-04-08 | Темпл Юниверсити-Оф Зэ Коммонвелс Систем Оф Хаер Эдьюкейшн | Новые функционализированные лактамы в качестве модуляторов 5-гидрокситриптаминового рецептора 7 и способ их применения |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201002563D0 (en) * | 2010-02-15 | 2010-03-31 | Cambridge Entpr Ltd | Compounds |
| WO2014164756A1 (en) * | 2013-03-11 | 2014-10-09 | Temple University Of The Commonwealth System Of Higher Education | Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use |
| WO2016040554A1 (en) * | 2014-09-10 | 2016-03-17 | Temple University-Of The Commonwealth System Of Higher Education | Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use |
| IL309982A (en) * | 2016-11-15 | 2024-03-01 | Univ Temple | New modulators of 5-hydroxytryptamine receptor 7 and a method of using them |
| JP7365238B2 (ja) | 2017-03-21 | 2023-10-19 | テンプル・ユニバーシティ－オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション | ５－ヒドロキシトリプタミン受容体７調節物質および治療剤としてのその使用 |
| WO2019094856A1 (en) * | 2017-11-13 | 2019-05-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Atypical inhibitors of monoamine transporters; method of making; and use thereof |
| EA202092328A1 (ru) * | 2018-05-11 | 2021-04-08 | Темпл Юниверсити-Оф Зэ Коммонвелс Систем Оф Хаер Эдьюкейшн | Новые функционализированные лактамы в качестве модуляторов 5-гидрокситриптаминового рецептора 7 и способ их применения |
-
2020
- 2020-11-12 CA CA3160801A patent/CA3160801A1/en active Pending
- 2020-11-12 MX MX2022005820A patent/MX2022005820A/es unknown
- 2020-11-12 JP JP2022527717A patent/JP7730811B2/ja active Active
- 2020-11-12 EP EP20829736.6A patent/EP4058455A1/en active Pending
- 2020-11-12 AU AU2020381460A patent/AU2020381460A1/en active Pending
- 2020-11-12 US US17/776,533 patent/US20230002383A1/en active Pending
- 2020-11-12 CN CN202080093159.6A patent/CN115003675A/zh active Pending
- 2020-11-12 BR BR112022009374A patent/BR112022009374A2/pt unknown
- 2020-11-12 KR KR1020227019540A patent/KR20220113702A/ko active Pending
- 2020-11-12 WO PCT/US2020/060270 patent/WO2021097116A1/en not_active Ceased
- 2020-11-13 TW TW109139761A patent/TWI905129B/zh active
-
2022
- 2022-05-07 IL IL292811A patent/IL292811A/en unknown
-
2025
- 2025-08-18 JP JP2025135739A patent/JP2025161894A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021097116A1 (en) | 2021-05-20 |
| TWI905129B (zh) | 2025-11-21 |
| AU2020381460A1 (en) | 2022-06-09 |
| JP7730811B2 (ja) | 2025-08-28 |
| IL292811A (en) | 2022-07-01 |
| CN115003675A (zh) | 2022-09-02 |
| US20230002383A1 (en) | 2023-01-05 |
| JP2023501577A (ja) | 2023-01-18 |
| MX2022005820A (es) | 2022-08-16 |
| EP4058455A1 (en) | 2022-09-21 |
| JP2025161894A (ja) | 2025-10-24 |
| BR112022009374A2 (pt) | 2022-08-09 |
| KR20220113702A (ko) | 2022-08-16 |
| TW202132301A (zh) | 2021-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2927231B1 (en) | Imidazopyridine compounds | |
| CN104822267B (zh) | 乙型肝炎病毒共价闭合环状dna形成的抑制剂及其使用方法 | |
| CA2734415C (en) | Picolinamide derivatives as kinase inhibitors | |
| KR102653190B1 (ko) | 고 활성 sting 단백질 작용제 화합물 | |
| CA3150400A1 (en) | Pyridine oxynitride, preparation method therefor and use thereof | |
| JP2020532552A (ja) | ブルトン型チロシンキナーゼＢｔｋの阻害および分解活性を有する化合物 | |
| EA039808B1 (ru) | Аминотриазолопиридины в качестве ингибиторов киназ | |
| WO2017114509A1 (zh) | 醛基类化合物及其制法和用途 | |
| JP2017533955A (ja) | イソインドリン誘導体、その中間体、製造方法、薬物組成物及び応用 | |
| CA3027416A1 (en) | Heteroaromatic derivatives as nik inhibitors | |
| WO2013138753A1 (en) | Prodrugs of riluzole and their method of use | |
| TW201111356A (en) | Nitrogen-containing compound and pharmaceutical composition | |
| JPWO2001079184A1 (ja) | 置換ピペラジン類 | |
| AU2011345969B2 (en) | Novel substituted isoquinoline derivative | |
| KR102293986B1 (ko) | 이소퀴놀리논 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 폴리(adp-리보스)폴리머라제-1(parp-1) 관련 질환의 예방 또는 치료용 약학적 조성물 | |
| CA3161590A1 (en) | Novel functionalized lactones as modulators of the 5-hydroxytryptamine receptor 7 and their method of use | |
| CN111377873B (zh) | 氨基嘧啶化合物及其制备方法和用途 | |
| JP7273722B2 (ja) | タウオリゴマーの形成を阻害する新規ベンゾフラン、ベンゾチオフェン及びインドール類似体並びにそれらの使用方法 | |
| EP3617204A1 (en) | Indoleamine 2,3-dioxygenase inhibitor and application | |
| WO2013192610A2 (en) | Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis | |
| CA3160801A1 (en) | Novel functionalized lactams as modulators of the 5-hydroxytryptamine receptor 7 and their method of use | |
| EP3956315B1 (en) | Benzo- and pyrido-pyrazoles as protein kinase inhibitors | |
| CN102653522B (zh) | ω-羧基取代的二苯基硫脲类化合物及其制备方法和用途 | |
| AU2011225108C1 (en) | Benzazepine compound | |
| CA2967694A1 (en) | Indole and azaindoles derivatives and their use in neurodegenerative diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240930 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240930 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240930 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20241112 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20241112 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241112 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241219 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20241219 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20241219 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241219 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250424 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250429 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251007 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251007 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20251126 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260326 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260408 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260408 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260408 |